Giancarlo Sborgia1, Alfredo Niro2, Valentina Pastore1, Rosa Anna Favale1, Alessandra Sborgia1, Samuele Gigliola3, Gianluigi Giuliani1, Maria Oliva Grassi1, Marco Coassin4, Francesco Aiello5, Cristiana Iaculli6, Michele Reibaldi7, Francesco Boscia1, Giovanni Alessio1. 1. Department of Medical Science, Neuroscience and Sense Organs, Eye Clinic, University of Bari, 70124, Bari, Italy. 2. Eye Clinic, Hospital "SS Annunziata", ASL Taranto, Via F. Bruno, 1, 74010, Taranto, Italy. alfred.nir@tiscali.it. 3. Eye Clinic, Hospital "SS Annunziata", ASL Taranto, Via F. Bruno, 1, 74010, Taranto, Italy. 4. Ophthalmology, University Campus Bio Medico of Rome, 00128, Rome, Italy. 5. Ophthalmology Unit, Department of Experimental Medicine, University of Rome "Tor Vergata", 00133, Rome, Italy. 6. Department of Ophthalmology, Policlinico Riuniti Di Foggia, University of Foggia, 71122, Foggia, Italy. 7. Department of Surgical Sciences, University of Torino, 10126, Turin, Italy.
Abstract
PURPOSE: To evaluate the mid-term safety and effectiveness of intravitreal dexamethasone implant (DEX-i) for treating unresponsive to medical therapy cystoid macular edema (CME) in vitrectomized eyes for endophthalmitis. METHODS: Retrospective and interventional case series study conducted on vitrectomized eyes for endophthalmitis that developed a CME that did not adequately respond to medical therapy, who underwent 0.7-mg DEX-i. Main outcome measures were changes in central retinal thickness (CRT) and best corrected visual acuity (BCVA). RESULTS: Eleven eyes were included in the study. Microbiological findings of vitreous biopsies were 7 (63.6%) staphylococcus epidermidis; 3 (27.3%) Pseudomonas aeruginosa; and 1 (9.1%) Propionibacterium acnes. Median (interquartile range, IqR) duration of CME was 4.0 (3.0-4.0) months. Median (IqR) time between vitrectomy and DEX-i was 9.0 (9.0-11.0) months. Median CRT was significantly decreased from 548.0 (412.8-572.5) µm at baseline to 308.0 (281.3-365.5) µm at month 6 (p = 0.0009, Friedman test). Median BCVA significantly improved from 38.0 (30.5-44.8) letters at baseline to 50.0 (46.8-53.0) letters at month 6 (p < 0.0001, Friedman), with 9 (81.8%) eyes gaining ≥ 10 letters. Elevation of intraocular pressure was observed in one (9.1%) eye, which was successfully controlled with medical therapy. No recurrence of endophthalmitis or other complications was observed. Eight (72.7%) eyes required an additional DEX-i, while 3 (27.3%) were successfully controlled with only one DEX-i. CME recurrence occurred in 5 (62.5%) Gram-positive and 3 (100.0%) Gram-negative bacteria (p = 0.2357). CONCLUSION: In vitrectomized eyes for endophthalmitis affected by CME unresponsive to medical therapy, DEX-i had an acceptable safety profile and achieved favorable outcomes. The possibility of suppressing mechanisms for infection control should be taken into account, although correct management of endophthalmitis and long time without reactivation before DEX-i reduce the risk.
PURPOSE: To evaluate the mid-term safety and effectiveness of intravitreal dexamethasone implant (DEX-i) for treating unresponsive to medical therapy cystoid macular edema (CME) in vitrectomized eyes for endophthalmitis. METHODS: Retrospective and interventional case series study conducted on vitrectomized eyes for endophthalmitis that developed a CME that did not adequately respond to medical therapy, who underwent 0.7-mg DEX-i. Main outcome measures were changes in central retinal thickness (CRT) and best corrected visual acuity (BCVA). RESULTS: Eleven eyes were included in the study. Microbiological findings of vitreous biopsies were 7 (63.6%) staphylococcus epidermidis; 3 (27.3%) Pseudomonas aeruginosa; and 1 (9.1%) Propionibacterium acnes. Median (interquartile range, IqR) duration of CME was 4.0 (3.0-4.0) months. Median (IqR) time between vitrectomy and DEX-i was 9.0 (9.0-11.0) months. Median CRT was significantly decreased from 548.0 (412.8-572.5) µm at baseline to 308.0 (281.3-365.5) µm at month 6 (p = 0.0009, Friedman test). Median BCVA significantly improved from 38.0 (30.5-44.8) letters at baseline to 50.0 (46.8-53.0) letters at month 6 (p < 0.0001, Friedman), with 9 (81.8%) eyes gaining ≥ 10 letters. Elevation of intraocular pressure was observed in one (9.1%) eye, which was successfully controlled with medical therapy. No recurrence of endophthalmitis or other complications was observed. Eight (72.7%) eyes required an additional DEX-i, while 3 (27.3%) were successfully controlled with only one DEX-i. CME recurrence occurred in 5 (62.5%) Gram-positive and 3 (100.0%) Gram-negative bacteria (p = 0.2357). CONCLUSION: In vitrectomized eyes for endophthalmitis affected by CME unresponsive to medical therapy, DEX-i had an acceptable safety profile and achieved favorable outcomes. The possibility of suppressing mechanisms for infection control should be taken into account, although correct management of endophthalmitis and long time without reactivation before DEX-i reduce the risk.
Authors: Joan-En Chang-Lin; James A Burke; Qing Peng; Ton Lin; Werhner C Orilla; Corine R Ghosn; Kai-Ming Zhang; Baruch D Kuppermann; Michael R Robinson; Scott M Whitcup; Devin F Welty Journal: Invest Ophthalmol Vis Sci Date: 2011-06-28 Impact factor: 4.799
Authors: Karlijn F de Nie; N Crama; Maurits A D Tilanus; B Jeroen Klevering; Camiel J F Boon Journal: Graefes Arch Clin Exp Ophthalmol Date: 2012-12-19 Impact factor: 3.117
Authors: Stephen J Kim; Daniel F Martin; G Baker Hubbard; Sunil K Srivastava; Jiong Yan; Chris S Bergstrom; Thomas M Aaberg Journal: Ophthalmology Date: 2009-06-05 Impact factor: 12.079
Authors: Jennifer E Thorne; Elizabeth A Sugar; Janet T Holbrook; Alyce E Burke; Michael M Altaweel; Albert T Vitale; Nisha R Acharya; John H Kempen; Douglas A Jabs Journal: Ophthalmology Date: 2018-09-27 Impact factor: 14.277
Authors: Vito Romano; Martina Angi; Fabrizio Scotti; Renata del Grosso; Davide Romano; Francesco Semeraro; Paolo Vinciguerra; Ciro Costagliola; Mario R Romano Journal: Mediators Inflamm Date: 2013-10-30 Impact factor: 4.711